It has been suggested that cancer types with high occurrences of p53 mutations, such as PDAC where approximately 60% of patients have mutant p53, may experience increased sensitivity to WEE1 targeted drugs as a result of their functionally inactive G1/S checkpoints (https://www.cbioportal.org/). The gene discussed is TP53; the disease is cancer.